AzTrials
AzTrials

EpilepsyPhase 2NCT00965575

Pilot Study of Melatonin and Epilepsy

A Phase 2 study testing Melatonin in people with Epilepsy, run by Children's Hospital Medical Center, Cincinnati at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The prevalence of epilepsy is 1% in the USA. About 30% of epilepsy patients eventually become refractory to medical treatment. Co morbid conditions are becoming as important as seizure control as these affect overall wellbeing. Read more about this study

Who is it for?
Ages 6 to 11 years
Conditions the study is for
Epilepsy
What is being tested?
Melatonin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
11 participants
Where
1 siteUnited States
Study dates
Jun 2011to Aug 2014
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 11 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Age 6-11 years (prepubertal based on tanner staging)
  • Patients with epilepsy (diagnosis based on ILAE).
  • Normal intelligence based on school placement (defined as age appropriate; an IEP due to epilepsy related causes is acceptable as is placement in a higher grade) or IQ>70 (testing done with in 12 months of enrollment)
  • No history of significant snoring- loud snoring every night outside of a room with closed door
  • Combined score of 30 or more on sleep fragmentation, parasomnia and daytime drowsiness subscales on SBQ.

Who cannot join

  • History of significant snoring- loud snoring every night heard outside of a room with closed door
  • Diagnosis of obstructive sleep apnea (OSA) or periodic limb movement disorder on PSG
  • Vagus nerve stimulator implanted
  • History of a major psychiatric disease (e.g. psychosis, major depression)
  • History of autism or pervasive development disorder
  • Severe neuro-developmental disabilities, as determined by PI
Show all 13Show fewer
  • Clinically significant systemic organic disease, as determined by PI
  • Current use of melatonin or sustained release melatonin
  • Prior use of sustained release melatonin
  • Current use of any hypnotic medications except for medications used as a rescue treatment for seizures
  • Use of psychoactive or stimulant medication for attention deficit disorders
  • Subjects with immune disorders, lympho-proliferative disorders, and those taking oral corticosteroids or other immuno-suppressants
  • Subject or parent/legal guardian might not be reasonably expected to be compliant with or to complete the study.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229

Other trials in United States

About this study

Official title: Melatonin and Sleep in Patients With Epilepsy

The prevalence of epilepsy is 1% in the USA. About 30% of epilepsy patients eventually become refractory to medical treatment. Co morbid conditions are becoming as important as seizure control as these affect overall wellbeing. Sleep related complaints are frequent in them including, frequent arousals, difficulty falling asleep and excessive daytime sleepiness. Polysomnography shows increased arousal index, sleep onset latency, and stage shifts and fragmented REM sleep. Poor sleep efficiency causes daytime fatigue, poor cognition and behavior and can worsen seizure control. Stabilizing sleep may improve seizure control. Melatonin is a naturally occurring hormone in the body involved in the regulation of circadian rhythm and exogenously given, has been shown to decrease sleep onset latency, arousals, and there-by increase sleep efficiency in healthy pediatric patients. Similar data does not exist in the patients with epilepsy. As sleep has important impact on epilepsy and overall functioning, it is important to study effect of melatonin in children with epilepsy.

We propose a randomized double blind placebo controlled trial with a cross-over design. Our hypothesis is that, for patients with epilepsy, administration of melatonin 30 minutes before bedtime for four weeks may:

  • Improve the quality of sleep;
  • Improve daytime functioning in terms of cognition, behavior and quality of life;
  • Decrease epileptic potential. We will use polysomnography, electroencephalogram, psychomotor vigilance task, seizure diary, and questionnaires to assess the effect of melatonin on these domains. This study may help to improve the care of children with epilepsy.
Read the detailed description

Hypothesis 1: Melatonin treatment improves the quality of sleep in patients with epilepsy.

Various studies evaluating sleep problems in patients with epilepsy using questionnaires have shown that 34-45% patients have sleep related problems [1-3]. Cortesi et al reported that children with seizures had higher sleep difficulties than their siblings and controls[4]. Bedtime difficulties, sleep fragmentation, daytime sleepiness, snoring and parasomnia were reported as sleep problems in this population [2, 4]. Patients with refractory seizures and using multiple antiepileptic drugs(AED) showed worse problems[5]. On polysomnography (PSG) these patients show increased arousal index, increased sleep onset latency, fragmented or reduced REM sleep, increased stage shifts and increased Stage 1 sleep and decreased stage 2 and slow wave sleep. [6-9] Melatonin has been shown to decrease sleep onset latency and increase total sleep time and subjectively improve sleep in healthy individuals.[10-15]. Various studies using fast release and sustained release formulations have suggested improvement in sleep efficiency and decreased arousals as well.[16-18] In a randomized placebo controlled study by Gupta et al[19], Melatonin was shown to subjectively improve sleep in patients with epilepsy. Studies in children with neurodevelopmental delay and autism along with epilepsy have also reported similar findings.[17, 20-23] Rationale: There are significant sleep disturbances in children with epilepsy. Melatonin has been shown to improve sleep in this group of patients. However, all these studies report improvement based on parent report and only one study is placebo-controlled. Our study will assess this in randomized placebo controlled fashion and will provide both subjective and objective improvement in sleep with the primary outcome being improved sleep efficiency on PSG.

Hypothesis 2: Melatonin improves daytime functioning in terms of cognition, behavior and quality of life in the patients with epilepsy.

Poor sleep and epilepsy both have detrimental effect on cognition.[24-27] Melatonin by improving sleep may improve cognitive functioning in these patients.

Some patients with epilepsy have poor behavior and psychiatric function.[28-30] Severity of these problems are related to the worsening of the sleep problems.[2, 4] Melatonin by improving sleep may improve the behavior in these patients.

Epilepsy has negative effect on various aspects of the patients' life including social, behavioral, and academic [31, 32]. Questionnaires have been developed to assess the impact on overall quality of life of the patients [33, 34]. These tools are helpful to quickly and subjectively assess quality of life. Based on these studies, it has been shown that patients with refractory seizures have poor quality of life [33-37] and an improvement is seen if the seizure frequency is decreased.[38-41] There has been only one study reporting quality of life (QOL) after use of melatonin in patients with epilepsy. In this randomized placebo controlled study, significant improvement was seen in the cognitive, anxiety and behavior subscales of the QOLCE after use of melatonin.[42] To date, there are no studies reporting on the effect of melatonin on cognition or behavior in epilepsy patients.

Rationale: Poor behavior, cognition and quality of life have been reported in children with epilepsy and sleep disturbances. By improving the quality of sleep, melatonin will improve all these domains. QOLCE has been validated and used in epilepsy patients and will assess the QOL in these patients. Vigilance is the component of cognition that is most consistently and drastically affected by sleep deprivation. PVT measures "vigilant attention" and has been used widely in adult patients to assess the effect of sleep deprivation on cognition. It has been described as a very sensitive measure to see both acute and chronic effects of sleep deprivation. BASC-PRS has been used to assess behavior in children and is found equally useful in epilepsy patients as child behavior check list (CBCL). It is a sensitive tool to compare changes over shorter time span.

Hypothesis 3: Melatonin treatment decreases epileptic potential. Sleep deprivation has been known to induce seizures and epileptic discharges on EEG[43]. Seizures are also known to occur with change in the depth or rhythmicity of sleep.[43] Patients with epilepsy report sleep deprivation as a significant seizure precipitating factor [44, 45]. In a recent study, Haut et al reported that one hour of additional sleep on the preceding night decreased relative odds of a seizure on the subsequent day to 0.91[46]. In a study Oliveira reported that treatment of obstructive sleep apnea (OSA) decreased interictal epileptiform discharges.[47] The belief that fewer epileptiform discharges represent better seizure control is controversial. But a study suggested that decreasing epileptiform discharges on EEG improves behavior.[48] Studies investigating obstructive sleep apnea in patients with epilepsy have reported improvement in seizure control with treatment of OSA [49-54]. These suggest that stabilizing sleep has a beneficial effect on seizure control.

Many studies that evaluated melatonin in epilepsy patients report overall improvement in seizure control[17, 21], while others report no worsening of seizure control after the use of melatonin[20, 22, 23]. Coppola et al reported inconclusive results with regards to seizure control after melatonin use[55]. However, these studies are not powered to account for variability in seizure occurrence reported with epilepsy patients.

Rationale: There are no randomized controlled studies available to evaluate the effect of melatonin on seizure control in the children with epilepsy. This study will identify the effect of short term use of melatonin compared with placebo and will provide pilot data to evaluate this effect in a larger trial in future.

Conditions
Epilepsy
Being tested
Melatonin, Placebos
Keywords
epilepsy, sleep, seizures, cognition
Medical subject headings
Epilepsy, Seizures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MelatoninDrug

    Also called natural supplement

    Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.

  • PlacebosDrug

    Also called Placebo

    Placebo. Taken 30 minutes prior to bedtime for four weeks.

Study groups in NCT00965575
Study groupRoleWhat they receive
MelatoninExperimentalSubjects will take sustained release melatonin 30 minutes prior to bedtime for four weeks
Receives: Drug: Melatonin
PlacebosPlacebo comparatorSubjects will take a placebo 30 minutes before bedtime for four weeks
Receives: Drug: Placebos

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sleep Latency Wakefulness After Sleep Onset (WASO)

    Sleep Latency Wakefulness After Sleep Onset (WASO). Calculated as the sum of wake time minutes from sleep onset to the final awakening.

    Measured: 13 weeks

Secondary outcomes (1)
  1. Seizure Frequency

    Seizure frequency was determined by parent/caregiver report on a seizure diary which was filled out after each seizure which is an accepted patient-reported outcome measure. Data is given as number of seizures per month.

    Measured: 13 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Aug 2009 (estimated)
  2. Study startJun 2011
  3. Primary completionJun 2014
  4. Study completionAug 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00965575
Sponsor's protocol ID
2009-1042
Status last verified
Feb 2017
First submitted
24 Aug 2009
Last updated
1 Oct 2020
Data monitoring committee
Yes
Individual data sharing
No: There is no plan to share data at this time.

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Melatonin in people with Epilepsy, run by Children's Hospital Medical Center, Cincinnati at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 1 Oct 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sleep Latency Wakefulness After Sleep Onset (WASO) (time frame: 13 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Oct 2020; AzTrials last refreshed its copy on 26 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in